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Penetration of the blood-brain barrier and anti-tumour 
effect of a novel PLGA-lysoGM1/DOX micelles drug 
delivery system 
1Ying Yin, 1Jun Wang, 1Meng Yang, 1Ruolin Du, 3Giuseppe Pontrelli, 4Sean McGinty, 
1Guixue Wang, 1Tieying Yin*, and 1,2Yazhou Wang* 
Effective treatment of glioma and other central nervous system (CNS) diseases is hindered by the presence of 
the blood-brain barrier (BBB). A novel nano-delivery vehicle system comprised of PLGA-lysoGM1/DOX 
micelles was developed to across the BBB for CNS administration. We have shown that Doxorubicin (DOX) as 
a model drug encapsulated in PLGA-lysoGM1 micelles, can achieve up to 3.8% loading efficiency and 61.6% 
encapsulation efficiency by the orthogonal test design. Our in vitro experiments demonstrate that PLGA-
lysoGM1/DOX micelles have a slow and sustainable drug release under physiological conditions and exhibit a 
high cellular uptake through the macropinocytosis and the autophagy/lysosomal pathways. In vivo 
experimental studies in zebrafish and mice confirmed that PLGA-lysoGM1/DOX micelles could across the BBB 
and specifically accumulated in the brain. Moreover, an excellent anti-glioma effect presented in intracranial 
glioma-bearing rat. Therefore, PLGA-lysoGM1/DOX micelles not only effectively acrossed the BBB, but our 
results suggest it has a great potential for anti-glioma therapy and other central nervous system diseases.   
Introduction
Glioma is the most frequent and aggressive form of the 
malignant primary brain tumour, causes one of the world’s 
most devastating diseases.1 Despite the multimodal 
treatments of aggressive surgical resections with radiotherapy 
and/or chemotherapy in clinics, the current prognosis for 
patients with glioma remains dismal, patients with glioma have 
a median survival time of 12–15 months and the five-year 
survival rate less than 4%.2-4 The main obstacle for brain 
tumour treatment is to deliver chemotherapeutics at 
efficacious levels to the site of tumour, as the insufficient 
tumour targeting strategies and limited drug delivery through 
the blood-brain barrier (BBB) after systemic administration.5, 6 
To date, various invasive and non-invasive strategies have 
been investigated to enhance drug delivery to the brain 
whereas most of the invasive approaches still exists the risk of 
the nerve damage and intracranial infection.7    
Notably, designing advanced nanocarriers with high 
specificity for intracranial drug delivery has attracted great 
attention on non-invasive permeation the BBB，are emerging 
as a powerful drug-delivery platform for glioma treatment.8, 9 
Non-invasively permeable BBB nanocarrier materials generally 
include inorganic, organic nanomaterials.10 With the 
remarkable advancements in nanotechnology, a variety of 
inorganic/organic nanomaterials with surface modification of 
BBB-targeting ligands and/or cellpenetrating peptides (CPPs) 
have been created to across the BBB for highly accurate 
theranostics of brain tumours.11 Meanwhile, accumulated 
reports show that transcytosis appears to be the most likely 
mechanism, despite the controversy about the exact 
mechanism of nanocarriers penetrating the BBB. In general, 
the size, charge, shape and surface morphology of 
nanocarriers are related to the transcytosis process. Surface 
modifications with different ligands can further increase the 
efficiency of overcoming the BBB due to activating specific 
transport- and receptor-mediated transcytosis pathways.12 
However, the design of nanocarriers that can across the BBB 
with high efficiency is, a formidable challenge.13 Therefore, 
searching for new methods to improve the efficiency of 
acrossing the BBB with excellent safety and stability is urgently 
needed.
Monosialotetrahexosylganglioside (GM1) is composed of a 
hydrophilic sugar chain and a lipophilic ceramide. It is a major 
component of mammalian gangliosides.14 GM1 plays an 





































































indispensable role in neurogenesis, neural cell growth, and 
differentiation,15 and can promote the survival and regrowth 
of injured neurons.16 Importantly, exogenous GM1 and its 
derivatives can also across the BBB.17, 18 We previously 
demonstrated that GM1 micelles loaded with DOX could 
efficiently penetrate the BBB.19 The specific mechanism of 
action of GM1 acrossing the BBB is still ill-defined. Moreover, 
GM1 self-assembled micelles are small molecule systems, and 
the preparation of high molecular weight micelle systems is 
more stable than small molecule micelle systems,20 has better 
load capacity, and better structural advantages in the next 
modification. However, the hydrophilic sugar chain appears to 
be the key to GM1 and its derivatives being able to across the 
BBB.21 The lysoGM1 is a hydrolysis product of GM1 with
Fig. 1 Synthesis and Characterization of PLGA-lysoGM1. (a) A schematic diagram of PLGA-lysoGM1/DOX micelles formation. (b) 
The FTIR spectrum of the synthesised PLGA-lysoGM1 sample. (c) The 1H NMR spectrum of PLGA-lysoGM1. (d) The 13C NMR 
spectrum of PLGA-lysoGM1.
hydrophilic sugar chains structures, and its –amine (-NH2) 
group can successfully synthesize micelles with a hydrophobic 
compound containing a –carboxylic (-COOH) group. It is thus 
expected that lysoGM1 may provide a new way to promote 
efficient drug delivery across the BBB. 
The US Food and Drug Administration (FDA) has 
recognized that poly(lactic-co-glycolic acid) (PLGA) exhibits 
high biocompatibility, biodegradability and controlled drug 
release properties in vivo, so it is widely used in various clinical 
medical researches of humans.22 We therefore proposed to 
design and develop PLGA-lysoGM1 micelles containing the 
anti-cancer drug DOX, which has been shown to effectively 
induce apoptosis in resistant glioma cells. Further to the 
advantages mentioned above, the hydrophilic group activates 
the BBB transport channels and receptors, when modified with 
lysoGM1. These nanoparticles (NPs) are able to across the BBB 
and penetrate into the glioma area. The uptake mechanism of 
PLGA-lysoGM1/DOX micelles is also explored in this study. This 
research may contribute to providing a promising option for 
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non-invasive drug delivery to glioma and other central nervous 
system diseases.
Results and discussion
Characterization of PLGA-lysoGM1/DOX micelles and DOX release 
in vitro 
The procedure for the synthesis of PLGA-lysoGM1/DOX 
micelles is presented in Fig. 1a. Firstly, PLGA-lysoGM1 was 
synthesized by amide condensation, and then because of the 
amphiphilic properties of the PLGA-lysoGM1, micelles 
composed of PLGA-lysoGM1 polymer were formed by self-
assembling in an aqueous solution (Fig. 1a). Finally, DOX was
Fig. 2 Characterization of PLGA-lysoGM1/DOX micelles and DOX release in vitro. (a) TEM image and DLS analysis of PLGA-
lysoGM1, scale bar = 100 nm. (b) TEM image and DLS analysis of PLGA-lysoGM1/DOX micelles, scale bar = 100 nm. (c) and (d) 
Simulated and experimental drug release profile of DOX from PLGA-lysoGM1/DOX micelles at pH 5.4 and pH 7.4 37° C in PBS 
buffer. Data presented as mean ± SD of three separate experiments.
incorporated into the core of the micelles via hydrophobic 
interaction (Fig. 1a, the structure of R is shown in Fig. S2†). The 
synthesis of PLGA-lysoGM1 polymer was confirmed by fourier 
transform infrared spectroscopy (FTIR), 1H nuclear magnetic 
resonance (1H NMR) and 13C nuclear magnetic resonance （13C 
NMR）  (Fig. 1a-c). As shown in Fig. 1b, there were significant 
differences between the PLGA and PLGA-lysoGM1 infrared 
spectra, with the latter showing a specific absorption peak at 
1677 cm-1, a characteristic absorption peak of amide I band, 
belonging to C = O stretching vibration for the PLGA-
lysoGM1.23 Compared to the 1H NMR spectrum of PLGA, PLGA-
lysoGM1 increased four absorption peaks, 0.8 ppm, 1.2 ppm, 
1.9 ppm, and 7.9 ppm, respectively（Fig. 1c). The absorption 
peak at 0.8 ppm represents the proton in the methyl group in 
the saturated hydrocarbon (Fig. S2†). 1.2 ppm represents the 
proton in methylene in the saturated hydrocarbon (the m peak 
in Fig. S2 † ). The absorption peak at 1.9 ppm indicates the 
adjacent proton in the carbonyl region (the n peak in Fig. S2†), 
and the absorption peak at 7.9 ppm demonstrates the 
presence of amide bond by the proton synthesized chemically 
peak (Fig. S2 † ). Compared with the 13C NMR spectrum of 
PLGA, PLGA-lysoGM1 adds 5 absorption peaks, such as the 
absorption peaks labels a, f, b, d (Fig. 1d). These absorption 
peaks indicated that the PLGA was linked to a side chain 
containing a methyl carbon and several methylene groups. 
These results confirm the successful synthesis of the PLGA-
lysoGM1 polymer.
The FTIR spectrum of PLGA-lysoGM1 shown in Fig. 1b 
demonstrates that the PLGA and lysoGM1 molecules are 
linked by an amide group. The measured shift value of the 1H 
NMR spectrum of PLGA-lysoGM1 shown in Fig. 1c: 1.6 ppm, 
5.2 ppm, 4.8 ppm, 7.3 ppm, gives results in agreement with 
those the literature.24 PLGA-lysoGM1 by amide synthesis is 
confirmed by the 7.9 ppm shift. Analysis of the 13C NMR 
spectrum in Fig. 1d revealed that the nuclear magnetic carbon 
spectrum of PLGA-lysoGM1 increased the absorption peaks of 





































































long-chain methylene carbon, terminal methyl carbon and 
carbonyl carbon compared with PLGA, indicating that PLGA is 
combined with lysoGM1 having a long fatty chain of a carbonyl 
group to form PLGA-lysoGM1. In summary, the synthesis of 
PLGA-lysoGM1 was successfully achieved and confirmed by 1H 
NMR, 13C NMR and FTIR.
The morphology of the spherical PLGA-lysoGM1 and 
PLGA-lysoGM1/DOX micelles was illustrated by transmission 
electronic microscopy (TEM). As shown by TEM, the PLGA-
lysoGM1 and PLGA-lysoGM1/DOX micelles had an average size
 of 33.3 nm (Fig. 2a) and 27.8 nm (Fig. 2b), respectively. 
However, the dynamic laser scattering (DLS) analysis revealed 
that the PLGA-lysoGM1 and PLGA-lysoGM1/DOX micelles 
aggregated to particles with average sizes of 110 nm (Fig. 2a) 
and 246.8 nm (Fig. 2b), respectively. The zeta potential 
measurement indicated a negatively charged surface 
respectively at -34.9 mV and -33.2 mV (Fig. S4†). The DLS 
results showed that PLGA-lysoGM1/DOX micelles had a 
uniform spherical morphology with an increased size around 
136.8 nm compared with PLGA-lysoGM1 micelles (Fig.
Table 1. Best fitting parameters of the mathematical model of drug release.
2a and b), thus the results implied PLGA-lysoGM1/DOX 
micelles and control NPs were successfully prepared. In 
addition, the potentials of PLGA-lysoGM1 and PLGA-
lysoGM1/DOX micelles respectively are -34.9 mV and -33.2 mV 
(Fig. S4†). To best of our knowledge, the higher zeta potential, 
particles has the higher stability, can prevent particles from 
accumulating during storage.25 Contrasting cationic NPs, 
anionic NPs caused less damage to cell membrane integrity, 
weaker damage to lysosomes and mitochondrial 
membranes,26 and fewer neuronal toxicities. In summary, 
PLGA-lysoGM1/DOX micelles are stable and have better 
advantages in the next step of scientific research in this field.
The release kinetics of PLGA-lysoGM1/DOX micelles was 
then investigated in milieus simulating tumour tissue and 
intracellular acidity (Fig. 2c). When the pH was decreased from 
7.4 to 5.4, PLGA-lysoGM1/DOX micelles showed only a slight 
increasing in the accumulative release plateau (Fig. 2c), which 
was due to when the pH approached 5.4, simulating the 
endosomal pH environment, the drug release of PLGA-
lysoGM1/DOX micelles was rapidly enhanced by the additional 
H+. In addition to the experiments, following our previous 
work,27 we tested the ability of a diffusion-based mathematical 
model of biphasic drug release to describe the drug release 
process. The model assumes that the particles may be 
described as a biphasic material, with two distinct release 
rates (slow and fast). For full details of the model, the reader is 
referred to the Section 4 of Experimental section. The total 
cumulative release of DOX was 56.7% (pH 5.4) and 36.6% (pH 
7.4), over a period of 5 days (Fig. 2c, d). DOX was released 
rapidly within the first 10 h (hour), with 46.0% and 32.0% 
released for pH 5.4 and pH 7.4, respectively. Subsequent 
release was significantly slower, with only a further 9.7% and 
4.6% released for pH 5.4 and pH 7.4, respectively, over the 
remainder of the 120 h studied. The release rate decreased 
gradually (Fig. 2c). The cumulative release of DOX at pH 5.4 
was significantly higher than at pH 7.4. Following a standard 
least squares approach, we used the analytical solution of the 
mathematical model (Equation (2) of the Section 4 of 3 
Experimental section) in conjunction with the experimental 
data points to inversely estimate the three unknown 
parameters of the model for each pH (Table 1). Interestingly, 
whilst the fast release rate is comparable for the different pH 
conditions, the slow release rate is an order of magnitude 
faster for pH 5.4 compared with pH 7.4. The larger fraction of 
drug initially residing within the slow release route, coupled 
with the significantly reduced slow release rate, ensures that 
the drug release profile under pH 7.4 conditions is slower 
overall than that of pH 5.4. It is evident from Fig. 2c and 2d 
that the mathematical model captures the drug release 
profiles very well for each of the pH conditions tested. These 
experimental results confirmed a sustained release of DOX 
from PLGA-lysoGM1/DOX micelles in vitro, and moreover, a 
differential release profile depending on the pH of the 
environment.
The PLGA-lysoGM1/DOX micelles are formed through 
intermolecular forces, and represent a diffusion-controlled 
release system well-described by a biphasic mathematical 
model. The result demonstrates that the release of DOX from 
micelles is sustained with no burst release effect (Fig. 2c). The 
physical process of PLGA-lysoGM1/DOX micelles sustained 
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release is driven by the interaction between the hydrophobic 
drug DOX and the GM1 hydrophobic fragment.28 More 
critically, in the tumour-tissue microenvironment-mimicking 
milieu (pH 5.4).29 PLGA-lysoGM1/DOX micelles displayed 
considerable high release efficiency since the interior DOX 
could escape from the ruptured core-shell structure after 
equilibrium disruption of the micelles structure. After uptake 
by the tumour cells, the even lower intracellular pH finally 
caused micelles disassembly and drug release. So PLGA-
lysoGM1/DOX micelles promote drug release into tumour 
tissues, increasing the drug concentration within target 
tissues. Our mathematical model is able to capture the drug 
release under both pH conditions. However, the three 
parameters of the model are clearly pH-dependent (Table 1). 
This cal ls  for the development of more sophisticated 
mathematical models that are able to describe the pH-
dependence of these parameters and fully incorporate the 
underlying physics. In summary, PLGA-lysoGM1/DOX micelles 
have a good sustained release effect, and the in vitro pH-
sensitive release properties of micelles facilitate drug release 
in tumour tissues and cell sites, thereby increasing the drug 
c o n c e n t r a t i o n  o f  t a r g e t  t i s s u e s  o r
target cells.
  





































































Fig. 3 Evaluate of the mechanism of cellular uptake of PLGA-lysoGM1/DOX micelles. (a) Schematic illustration of PLGA-
lysoGM1/DOX micelles elicited anti-tumour against glioma. (b) The magnifed image showed PLGA-lysoGM1/DOX micelles across 
the BBB through macropinocytosis and the autophagy/lysosomal pathways. (c) and (d) The cellular uptake by CLSM after DOX 
solution, PLGA/DOX NPs and PLGA-lysoGM1/DOX micelles incubation with bEnd.3 and C6 for 30 min, 2 and 4 h, respectively 
(scale bars = 50 µm, 40 x objective). Magnfied fluorescence images (scale bars =10 µm, 40 x objective). (e) Fluorescence images 
showing one bEnd.3 cell after being treated with 6 inhibitors captures DOX (scale bars = 50 µm, 40 x objective), magnfied 
fluorescence images (scale bars = 10 µm, 40 x objective). (f) Relative fluorescence intensity of bEnd.3 cells after being treated 
with 6 inhibitors. Data presented as mean ± SD of three separate experiments. *: differences between control with other groups 
***P<0.001; **P<0.01.
Uptake mechanism of PLGA-lysoGM1/DOX micelles 
To investigate the internalization behavior of PLGA-
lysoGM1/DOX micelles and control formulations by bEnd.3 
cells and murine glioma cell line (C6) cells, the cellular uptake 
was qualitatively determined. Confocal laser scanning 
microscope (CLSM) showed obvious DOX fluorescence signal in 
bEnd.3 cells and C6 cells after 4 h incubation, suggesting these 
micelles were internalized into cells and released DOX within 
cells (Fig. 3c and d). Importantly, the fluorescence signal of the 
PLGA-lysoGM1/DOX micelles increased and was much stronger 
than that of control formulations（ free DOX and PLGA/DOX 
NPs ） after 4 h incubation (Fig. 3c), suggesting PLGA-
lysoGM1/DOX micelles promoted the cellular uptake through 
receptor mediated endocytosis pathway, which was due to the 
micelles displayed efflux transport inhibition and stopped DOX 
from being excluded by cells, thereby better ensuring that the 
toxic effects of DOX are carried out on the nucleus, especially 
cancer cells. This ultimately improves the efficiency of DOX. In 
recent years, numerous carrier-mediated transporters or 
receptors have demonstrated that the BBB has the capability 
to control the uptake of chemotherapeutics into the brain. 
Drug delivery systems (NPs, micelles, etc.) have been used to 
strengthen the ability of overcoming the BBB via binding 
between specific ligands located on the surface of the delivery 
system and the specific endogenous transporters localized on 
the BBB.30 The uptake of PLGA-lysoGM1/DOX micelles may be 
explained by the fact that some nanocarriers functionalized 
with GM1-targeting ligands could bind to BBB receptors and 
get transferred into the brain endothelial cells in vitro.31
It is well known that nanoparticles utilize different 
endocytosis mechanisms for cellular uptake. Generally, 
endocytosis can be divided into macropinocytosis, clathrin-
dependent endocytosis and caveolae-mediated endocytosis.32 
To elucidate the potential mechanism involved in the 
internalization behavior of PLGA-lysoGM1/DOX micelles, 
bEnd.3 cells were pre-incubated with various inhibitors and 
the inhibition rate was calculated to investigate the uptake 
mechanism. The endocytosis inhibitors used were 
chlorpromazine,33 filipin,34 rottlerin,35 brefeldin A,36  
colchicine36 and chloroquine.37 20
The cellular uptake of PLGA-lysoGM1/DOX micelles 
decreased to 80.7% and 73.0% after pre-incubation with filipin 
and brefeldin A for 1 h respectively and the cellular uptake 
decreased to 66.2% and 61.4% after pre-incubation with 
colchicine and chlorpromazine (Fig. 3e), indicating that filipin 
and brefeldin A mediated endocytosis pathway participated in 
the internalization of PLGA-lysoGM1/DOX micelles into cells. 
Colchicine and chlorpromazine decreased the uptake of PLGA-
lysoGM1/DOX micelles down to 66.2% and 61.4%, indicating 
macropinocytosis and clathrin mediated endocytosis pathway 
also involved in the internalization. Interestingly, rottlerin 
decreased the uptake of PLGA-lysoGM1/DOX micelles down to 
35.0%, indicating macropinocytosis-mediated endocytosis 
pathway played an important role in the internalization 
process of PLGA- lysoGM1/DOX micelles. Chloroquine resulted 
in a decrease of uptake to 31.5%, suggesting that 
autophagy/lysosomal pathways-mediated endocytosis was 
one of the major internalization pathways. In summary, 
micropinocytosis and the autophagy/lysosomal pathways were 
mainly involved in the internalization of PLGA-lysoGM1/DOX 
micelles (Graphical abstract), while other pathways such as 
receptor-involved clathrin mediated endocytosis and caveolae 
mediated endocytosis were also involved. 
This difference in uptake mechanisms is highly dependent 
on the particles physicochemical characteristics,  such as size
，charge, shape，potential surface ligand and conentration.38 
Zeta potentials of PLGA-lysoGM1/DOX micelles (-33.2 mV) 
revealed that micelles are highly anionic: usually anionic 
particles can enter cells by binding to the positive site of the 
membrane.39 On the other hand, negatively charged NPs show 
reduced protein adsorption, leading to longer circulation 
times.40 The PLGA-lysoGM1/DOX micelles size in aggregation 
occurs at the micro-scale (30-40 nm as measured by TEM). In 
fact, NPs with a size smaller than 200 nm (the estimated 
limiting size for a NPs to undergo endocytosis through a 
clathrin-mediated mechanism) have a greater chance to across 
the BBB efficiently.41 Actually, NPs larger than 1 μm are most 
likely to be engulfed via macropinocytosis, which is usually 
initiated by extensive plasma membrane reorganization or 
ruffling to form an external macropinocytic structure that is 
then enclosed and internalized.38 Macropinocytosis is 
dependent on microtubule function, and these structures are 
implicated in plasma membrane ruffling.42 It is important to 
note that our findings do not explain that the size of PLGA-
lysoGM1/DOX micelles was 30-40 nm as measured by TEM, no 
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more than 1 μm, but through the macropinocytosis mediate 
endocytic pathway, a matter of further investigation. The 
lysosome maintains its pH, but when chloroquine is added, it 
accumulates in acidic lysosomes, which increases the pH of 
lysosomes. In fact, the cumulative release of PLGA-
lysoGM1/DOX micelles at pH 5.4 was significantly higher than 
pH 7.4. Therefore, it was explained that the cellular uptake of 
PLGA-lysoGM1/DOX micelles was significantly reduced after 
adding chloroquine, further explaining that the PLGA-
lysoGM1/DOX micelle trans-membrane transport pathway was 
related to the chloroquine-mediated lysosomal-associated 
endocytosis pathway. Next, we further analyzed 
autophagy/lysosomal pathway-mediated endocytosis through 
subcellular localization, which was one of the major 
internalization pathways of PLGA-lysoGM1/DOX micelles.
Subcellular Localization
To further evaluate the autophagy/lysosomal pathways media 
ted endocytosis of PLGA-lysoGM1/DOX micelles, we further
Fig. 4 Intracellular subcellular organelle localization. (a) Distribution of PLGA-lysoGM1/DiI micelles at different time points, 
lysosome stained with LysoTracker DND-26 (green), mitochondria stained with MitoTracker Deep Red FM (purple, scale bars = 4 
µm, 63 x objective); (b) PLGA-lysoGM1/DiI micelles at trends of coincidence with lysosomes and mitochondria at different times; 
(c) Analysis of the degree of co-coincidence between PLGA-lysoGM1/DiI micelles and lysosomes and mitochondria (at each time 
point we select 10 sets of images for analysis to reduce the error).
qualitatively analyse the fluorescence overlay of DOX, 
lysosomes and mitochondria. Therefore, we studied the 
coincidence of PLGA-lysoGM1/DiI micelles with cell lysosomes 
and mitochondria by combining Fig. 4a with Image J's IntraCell 
plug-in for algorithmic analysis of pixel points and points 
between images. As shown in Fig. 4b at early times, PLGA-





































































lysoGM1/DiI micelles co-cultured with bEnd.3 cells for 2 h, the 
main micelles were dispersed in the cell membrane and 
cytoplasm, firstly combined with mitochondria most, indicating 
that under the mediated action of mitochondrial signal 
peptide, the micelles transfected into the cell and 
preferentially transported to the mitochondria. Only a small 
part of the lysosome overlaps and the fluorescence intensity 
was also weak, as the incubation time increases, it could be 
clearly observed that the fluorescence of micelles and 
lysosome had a certain degree of coincidence at 4 h. As 
micelles continued to across the membrane into the cell at 6 h, 
the distribution of micelles on the lysosome reached a 
significant turning point. Before this, the micelles accumulated 
on the lysosome and then began to decline while the 
distribution on the mitochondria was decreasing, indicating 
that some of the micelles accumulated on the mitochondria 
were transferred to the lysosomes. As shown in Fig. 4c, PLGA-
lysoGM1/DiI micelles can be co-ordinated with lysosomes and 
mitochondria at 
Fig. 5 Intracardiac injection of DOX solution, PLGA/DOX NPs and PLGA-lysoGM1/DOX micelles into transgenic (flk1: GFP) 
zebrafish. The white arrow indicates PLGA-lysoGM1/DOX micelles crossing out of vessels (the vessel is green). DOX retained 
within vessels without the PLGA-lysoGM1/DOX micelles was shown in red (20 min after injection). However, in the control group 
of DOX solution, cannot crossing out of vessels, and in the control group of PLGA/DOX NPs, having minute quantity of DOX 
crossing out of vessels. The white arrow indicates that PLGA-lysoGM1/DOX micelles can penetrate the BBB of zebrafish.
different time periods. Micelles are mainly distributed in 
lysosomes and mitochondria at 6 h, exhibiting a trend of 
increasing first and then decreasing. The implication that 
PLGA-lysoGM1/DiI micelles have obvious co-localization in the 
intracellular subcellular structure helps us to systematically 
better understand the process of micelles moving in cells.
The subcellular localization studies indicated that the 
PLGA-lysoGM1/DiI micelles were indeed taken up by the cells 
by a lysosomal-dependent uptake mechanism. Strikingly, the 
distribution of micelles in lysosomes and mitochondria is 
decreasing after 8 h; even then, the coincidence of micelles 
with mitochondria is still significantly higher than lysosomes at 
the later time of 48 h (Fig. 4), indicating that PLGA-
lysoGM1/DiI micelles can preferentially enter the 
mitochondria, have the ability to escape lysosomes, and are 
not easily excreted by cells, which is of great significance for 
anti-glioma treatment.
Transgenic fluorescent zebrafish for micelles to across BBB in vivo
We next explored the transcytosis of PLGA-lysoGM1/DOX 
micelles in vivo, using a zebrafish model. Zebrafish develop a 
mature BBB at 3 dpf and serve as a suitable model for BBB 
studies.43 We conducted intracardiac injection of PLGA-
lysoGM1/DOX micelles in 4 dpf (days post fertilization) Tag 
(flk1: GFP) zebrafish embryos and monitored the distribution 
of micelles in the brain through live imaging. At the time of 
imaging, the PLGA-lysoGM1/DOX micelles could exud 
extensively from blood vessels (green), as evidenced by the 
fluorescence of DOX (red) in the brain parenchyma (white 
arrow, Fig. 5). However, in the DOX solution control group, no 
DOX was observed in the brain and was indeed restricted to 
blood vessels, whereas weak DOX was observed in the brain in 
the PLGA/DOX NPs control group, which demonstrated that 
PLGA-lysoGM1/DOX micelles could effectively deliver drugs to 





































































brain tissue by overcoming the BBB. The PLGA-lysoGM1 
produced by chemical synthesis does not destroy lysoGM1 
activity and retain the hydrophilic sugar chain of lysoGM1, and 
t h u s  t h e  d r u g - l o a d e d  m i c e l l e s  c a n  a c r o s s  t h e  B B B .
Fig. 6 In vivo and ex vivo distribution. (a) In vivo fluorescence imaging of Kunming mice. (b) and (c) The content and ratio of DOX 
in CSF were detected by HPLC. Data presented as mean ± SD of three separate experiments. (d) Fluorescence images of whole 
body organs in mice treated with PLGA-lysoGM1/DOX micelles. (e) Quantification of the fluorescence signals from ex vivo organs 
from mice treated with PLGA-lysoGM1/DOX micelles. Data presented as mean ± SD of three separate experiments (***P<0.001).
In vivo distribution of PLGA-lysoGM1/DOX micelles
To explore the glioma-targeting and accumulating capacity of 
micelles, in vivo distribution of free DiR, PLGA/DiR NPs and 
PLGA-lysoGM1/DiR micelles in mice was monitored by a non-
invasive imaging system (IVIS) after intravenous injection for 1 
h, these PLGA-lysoGM1/DiR micelles exhibited fluorescence 





































































signal at brain site. As time extended, the intensity of these 
micelles in brain became stronger (Fig. 6a), and the fluorescent 
intensity of PLGA-lysoGM1/DiR micelles at brain site was much 
higher than that of control PLGA/DiR NPs, validating the 
prominent targeting capacity of PLGA-lysoGM1/DiR micelles 
that could improve brain distribution of nanoparticles (Fig. 6a). 
To clearly observe the distribution of PLGA-lysoGM1/DiR 
micelles in major organs of mice, which were collected at 30 
min, 90 min and 8 h and ex vivo imaging displayed a precise 
location of fluorescence signal of PLGA-lysoGM1/DiR micelles 
(Fig. 6d), which was further quantitatively analyzed (Fig. 6e). 
As anticipated, these PLGA- lysoGM1/DiR micelles exhibited 
similar fluorescence signal at brain site at 30 min and 90 min, 
which was enhanced at 8 h. Additionally, ex vivo imaging of 
major organs and semi-quantitative data showed that these 
nanoparticles were mainly distributed at liver and kidney (Fig. 
6a, d, e), suggesting liver and kidney were mainly involved in 
their metabolism and elimination.
Fig. 7 evaluation of anti-tumour efficacy of the PLGA-lysoGM1/DOX micelles in vivo. Images of tumours by (a) MRI. Localization 
of tumour lesion can be monitored in MRI (The red dotted line in the MRI image indicates the tumour). (b) Neuroscore and of (c) 
The survival time of different groups of tumour-bearing rats after various treatments. Study powered with seven mice per 
treatment arm for statistical significance.
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Here, to quantitatively analyse the distribution of PLGA-
lysoGM1/DOX micelles in the brain of mice, DOX was detected 
in the cerebrospinal fluid (CSF) after injection PLGA-
lysoGM1/DOX micelles by high performance liquid 
chromatography (HPLC). As shown in Fig. 6b, the 
concentration of DOX in CSF (the volume of CSF was assumed 
to be 350 μL) was highest, reaching up to 4375.5 ng/mL at 90 
min. In addition, the ratio of DOX in CSF (ratio of the amount 
of DOX detected in HPLC to the amount of DOX injected) 
shows a similar trend to the concentration (Fig. 6c). We know 
that PLGA-lysoGM1/DiR micelles have the hydrophilic sugar 
chain as GM1, which promotes trans-membrane transport. 
Furthermore, it has previously been reported in the 
literature44 that the inclusion of GM1 in liposomes significantly 
enhances the circulation time of liposomes in mice. Paclitaxel-
loaded GM1 micelles can form a complex with albumin in the 
blood, while albumin can target the gp60 receptor on 
endothelial cells, so this effect can promote the endocytosis of 
micelle particles. As a result, these data further confirm the 
capacity of PLGA-lysoGM1/DOX micelles to across the BBB 
with high efficiency.
Fig. 8 H&E staining, and immunohistochemical staining of GFAP and Ki-67 on day 20 after implantation. H&E (scale bars = 100 µm 
in 10 x objective, scale bars = 20 µm in 40 x objective) and GFAP (scale bars = 40 µm in 40 x objective) stained sections were 
observed for histology evaluation.
In vivo anti-glioma effect
Encouraged by in vitro and in vivo investigation, we further 
investigated the anti-glioma effect of PLGA-lysoGM1/DOX 
micelles after intravenous administration (Fig. 7, Fig. S7†). We 
first assessed the anti-glioma efficiency of PLGA-lysoGM1/DOX 
micelles after systemic administration using magnetic 
resonance imaging (MRI) in Fig. 7a, which showed the fast 
tumour growth in the control untreated group, while 
moderately restricted tumour growth was achieved in free 
DOX solution, free GM1 solution, as well as in mice treated 
with PLGA/DOX NPs after 20 days (d) tumour inoculation. 
However, we observed the strongest anti-tumour effect with 
PLGA-lysoGM1/DOX micelles, as evidenced by the nearly 
elimination most of the primary or thotopic tumours. We 
could know from the results that the neurological score of rat 
from each group were significantly affected by any of the 
treatments, with a similar variation to the survival rate 
(Fig.7b). As shown in Fig. 7c, the PLGA-lysoGM1/DOX micelles 
significantly extended mouse survival, which greatly prolonged 
and was 887.2% longer than that of saline group. Taken 





































































together, these results demonstrate that PLGA-lysoGM1/DOX 
micelles exhibit an excellent inhibitory effect on tumour 
growth and a prolonged survival for the glioma-bearing rat. 
The median survival time of C6 glioma-bearing rats 
treated with free DOX was prolonged from 15.6 to 21.4 d 
compared with saline group. The median survival time of mice 
treated with the free GM1 solution was 27.7 d, suggesting that 
GM1 solution improved the chemotherapeutic effect, which 
was mainly due to GM1 solution combines the advantages of 
anti-tumour effects and neuronal repair, resulting in a 
prolonged median survival time. While the PLGA/DOX NPs 
exhibited prolonged median survival time of 23.7 d, indicating 
these nanoparticles improved the therapeutic effect compared 
with DOX. Furthermore, the median survival time of PLGA-
lysoGM1/DOX micelles was as long as 138.4 d, which greatly 
prolonged and was 516.4% longer than that of GM1/DOX 
micelles group.19 The results implied that PLGA-lysoGM1/DOX 
micelles possessed an enhanced anti-glioma effect ， which 
was mainly due to that its ability to efficiently across BBB and 
enhance glioma cells growth inhibition. Moreover PLGA-
lysoGM1/DOX micelles promote functional recovery of 
damaged nerves, because GM1 has a certain nerve repair and 
protection effect, PLGA-lysoGM1 does not break the sugar 
chain structure of GM1, and the sugar chain structure is a 
functional group which may be neuroprotective and repair. 
Conclusively, the proposed PLGA-lysoGM1/DOX micelles have 
great promise to serve as a flexible and powerful system for 
treatment of glioma tumours as well as other brain diseases in 
CNS.
Immunohistochemical analysis 
To reveal the underlying mechanism that enabled prolonged 
survival, the C6 glioma-bearing brain slices were prepared and 
examined by hematoxylin-eosin (H&E) staining assay (Fig. 8). 
The morphologies of tumour cells from the PBS control group 
maintained normal with intact cell nuclei, while slight change 
occurred in the group of free DOX, which indicated their short 
survival time. In comparison, the tumour cells with shrinking 
and fragmented nuclei occurred in the free GM1 groups. It was 
noted that the nanoparticle therapy of PLGA/DOX NPs just 
induced partial cellular apoptosis because efficiently released 
DOX to glioma site. However, the most nuclear shrinkage and 
fragmentation, as well as the least tumour cells, appeared in 
the PLGA-lysoGM1/DOX micelles group, suggesting the 
occurrence of the severest tumour cell apoptosis. These 
phenomena suggest the enhanced efficiency in inhibiting 
glioma cells growth of PLGA-lysoGM1/DOX micelles, which is 
attributed to the superiority of nanoparticle /drug delivery.
However, H&E staining could not accurately reflect the 
apoptosis caused by different formulations, thus 
Immunohistochemical (IHC) staining of the tumour sections for 
GFAP and Ki-67 was used to evaluate the extent of astrocyte 
activation and the extent of tumour cell proliferation. Visually, 
the expression of GFAP was highest in the PLGA-lysoGM1/DOX 
micelles group, it was known that the higher positive 
expression of GFAP, the lower degree of malignancy of 
glioma,45 so further indicating that micelles had the most 
significant effect on glioma treatment. At the same time, 
PLGA-lysoGM1/DOX micelles treated group exhibited a 
significantly decreased Ki-67 expression (Fig. 8). Actually, the 
higher the expression of Ki-67, the higher the malignancy of 
tumour,46 indicating markedly reduced tumour cell 
proliferation after treatment.
Conclusion
This new PLGA-lysoGM1/DOX micelles was successfully 
designed and synthesized by our chemical synthesis that does 
not destroy the natural hydrophilic sugar chain of GM1. Firstly, 
these micelles were spherical and uniform micelles with a 
transverse diameter of 27.8 nm. Secondly, PLGA-lysoGM1/DOX 
micelles have sustainable pH-dependent drug release and this 
manuscript also contains mathematical and computational 
modelling, providing significant added value to the work and 
broadening the scientific appeal. Specifically, by adopting a 
continuum approach and approximating the PLGA-
lysoGM1/DOX micelles as a biphasic material, we provide a 
mathematical model that is capable of describing the pH-
dependent release of drug from the PLGA-lysoGM1/DOX 
micelles. Moreover, the PLGA-lysoGM1/DOX micelles could 
across the BBB via micropinocytosis and the 
autophagy/lysosomal pathways, also exhibit high 
biocompatibility, biodegradability and controlled drug release 
properties especially in the brain. Finally, these data strongly 
indicated that PLGA-lysoGM1/DOX micelles could dramatically 
enhance the efficacy of the anticancer drug DOX against 
intracranial glioma, which combined with the synergistic 
combination of improved nerve repair, could significantly 
prolong the survival time of glioma-bearing rats. PLGA-
lysoGM1/DOX micelles offer great potential for drug delivery 
to treat intracranial diseases such as brain tumours and 
neurodegenerative diseases.
Experimental section
C6 and bEnd.3 cells were purchased from Shanghai Zhongqiao 
Xinzhou Biological Technology Co., Ltd (Shanghai, China). DOX 
was purchased from meilunepharma (Dalian, People’s 
Republic of China). Purified GM1 were kindly provided by Huan 
Rui (Chongqing, People’s Republic of China). Dulbecco’s 
Modified Eagle’s Medium (DMEM) and Medium 1640 were 
purchased from HyClone (Logan, UT, USA). Trypsin (0.25%) was 
purchased from Thermo Fisher Scientific (Waltham, MA, USA). 
4′, 6-Diamidino-2-phenylindole (DAPI) was supplied by 
Beyotime Biotechnology (Shanghai, People’s Republic of 
China). Sphingolipid ceramide N-deacylase (SCDase) was 
supplied by Baori Doctors Technology (Beijing) Co., Ltd, 
Taurodeoxycholic acid hydrate (TDC) was purchased from 
Shanghai Maclean Reagent Biotechnology Co., Ltd. 1 
hydroxybenzotriazole (HOBt) was provided by Adamas 
Reagent Co., Ltd. Tri-n-butylamine (TBA)was provided by 
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Wuhan Kehaojia Biotechnology Co., Ltd. GFAP and Ki-67 were 
purchased from Shanghai Beyotime Biotechnology Co., Ltd. All 
other solvents used were of analytical grade. 
Synthesis and characterization of PLGA-lysoGM1
GM1 was hydrolyzed by hydrolase SCDase to form lysoGM1.47 
PLGA-lysoGM1 was synthesized by amide condensation 
reaction between PLGA and lysoGM1.48 Typically, PLGA (10 KD, 
1 g) and lysoGM1 were dissolved in 10 mL of dry N, N-
D i m e t h y l f o r m a m i d e  ( D M F ) .  S u b s e q u e n t l y ,  
NHydroxybenzotrizole (HOBt, 10.6 mg) and tributylamine (15.3 
μL) were added (lysoGM1: HOBt: tributylamine: PLGA=1 m：
1.8 m: 1.5 m: 0.3 m). The reaction mixture was stirred for 2 h 
at room temperature, and then the reaction product was 
isolated and purified by pre-cooled distilled water. Finally, the 
chemical structure of PLGA-lysoGM1 was analyzed by a FTIR 
spectrometer 5DX/550 (Nicolet, Madison, WI, USA) within the 
wavenumber range of 4000 cm-1 to 550 cm-1. 13C and with 1H
 NMR (Agilent 600 MHz, Agilent, Santa Clara, CA, USA) further 
confirmed the chemical structure of PLGA-lysoGM1. 
Characterization of PLGA-lysoGM1/DOX micelles and DOX release 
in vitro
Orthogonal experimental design (OED) method was used for 
constructing the best combination levels for different factors 
(Supplementary Table 1) to prepare PLGA-lysoGM1/DOX 
micelles.49 The micelle size and zeta potential were measured 
by DLS using a Zetasizer (Nano ZS90, Malvern, UK) and the 
refractive index was 1.57. The morphology of the micelles was 
characterized through TEM (JEM 1200 EX, Jeol, Tokyo, Japan). 
Ultraviolet spectroscopy (UV) followed to evaluate the drug 
loading and encapsulation efficiency of PLGA-lysoGM1/DOX 
micelles on a UV T6-New Century spectrophotometer (Purkinje 
General Instrument Co., Ltd. Beijing, China). 20 mg of 
lyophilized micelles was reconstituted in 5 mL of phosphate-
buffered saline (PBS, 0.01 M, pH 7.4 and pH 5.4), and this 
solution was introduced into a dialysis membrane (MWCO: 
8000). This dialysis membrane was placed in a 200 mL bottle 
containing 20 mL of PBS. Following this, the bottle was placed 
in a shaking incubator at a stirring speed of 100 rpm, 37° C. At 
selected time intervals, a 5 mL sample was collected with the 
replacement of the same volume of fresh PBS solution. The 
cumulative amount of DOX released was evaluated using 
ultraviolet detection at 480 nm.
Mathematical modelling of DOX release in vitro
We adopted a continuum approach and approximated the 
PLGA-lysoGM1/DOX micelles as a biphasic material, providing 
two release routes for the drug. These two routes could result 
from the particle preparation methods and may correspond to 
the drug phases being either fully embedded (slow release) or 
connected to the surface by pores or other defects (fast 
release). Each route of transport was associated with a 
different effective transport speed characterized by a rate 
constant Under the ideal assumptions that the drug 𝑘𝑖 , 𝑖 = 𝑓,𝑠. 
was uniformly distributed within each of the release routes, 
the release medium acted as an infinite sink and the drugs 
were dilute, and then considering drug transport within each 
route as a diffusion-dominated process, the following equation 
may be derived for the fraction of the initial mass of each drug 




― 𝐾𝑓(𝑛)𝑡 + (1 ― 𝑟)𝑒 ― 𝐾𝑠(𝑛)𝑡}
where         𝐴(𝑛) =
8
𝜋2(2𝑛 ― 1)2 𝐾𝑓(𝑛) =  
𝜋2(2𝑛 ― 1)2𝑘𝑓
4 𝐾𝑠(𝑛) =  
𝜋2(2𝑛 ― 1)2𝑘𝑠
4
and  is the initial fraction of drug within the fast release 𝑟
route. The cumulative fraction of drug released may then be 
calculated as . 1 ― 𝑀(𝑡)
Uptake mechanism of PLGA-lysoGM1/DOX micelles
The cellular uptake and uptake mechanism of the PLGA-
lysoGM1/DOX micelles were studied as we previously 
described.50, 51 C6 and bEnd.3 cells were seeded onto 24-well 
plates and allowed growing until 80% confluent. PLGA-
lysoGM1/DOX micelles and control formulations were added 
into medium and incubated for 0.5 h, 2 h, and 4 h in a CO2 
incubator. After incubation, cells were washed with PBS twice, 
fixed with 4% paraformaldehyde for 10 min at room 
temperature and then counterstained with DAPI for 10 min. 
Observations were carried out with a CLSM (TCS-SP2; Leica, 
Wetzlar, Germany). To evaluate the uptake mechanism of the 
PLGA-lysoGM1/DOX micelles, bEnd.3 cells were seeded at a 
density of 2 × 105 cells/well in 24-well plates and grown for 24 
h before incubation of inhibitors and PLGA-lysoGM1/DOX 
micelles. Cells were then treated with chlorpromazine (10 
μg/mL), filipin (5 μg/mL), rottlerin (10 μM), brefeldin A (5 μM), 
colchicine (10 μM) or chloroquine (10 μM) and in normal 
culture medium for 60 min at 37° C. Subsequently, PLGA-
lysoGM1/DOX micelles were added and incubation was 
continued for 4 h. Cells were then observed by a CLSM.
Subcellular localization
When 80% of bEnd.3 cells were fully adhered in a 24-well 
plate, PLGA-lysoGM1/DiI micelles (10 μg/mL) were co-cultured 
with bEnd.3 cells (2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h). Nuclei 
were stained with 2 g/mL Hoechst33342 (Shanghai 
Shengsheng Biological Technology Co., Ltd. Shanghai, China), 
mitochondria were stained with 100 nM MitoTracker Deep 
Red FM (Shanghai Shengsheng Biological Technology Co., Ltd., 
Shanghai, China), and lysosome were stained with 75 nM 
LysoTracker DND-26 (Shanghai Shengsheng Biological 
Technology Co., Ltd., Shanghai, China), followed by incubation 
in a cell culture incubator for 30 min. Images observed and 
collected under 63× magnification with a CLSM.
Transgenic fluorescent zebrafish for micelles to across the BBB in 
vivo 





































































PLGA-lysoGM1/DOX micelles were injected into zebrafish to 
qualitatively analyse the BBB penetration as we previously 
described.50 Transgenic fluorescent zebrafish (flk1: GFP) were 
incubated at 28° C according to standard zebrafish care and 
procedures. 4 dpf, zebrafish embryos were anesthetized with 
tracaine (4 g/L). Intracardiac injection with 5 nL DOX solution 
or PLGA/DOX NPs or PLGA-lysoGM1/DOX micelles then 
commenced, using a PV 820 Pneumatic PicoPump. This was 
followed by fixing with 1.2% low-melting point agarose. Finally, 
these embryos were observed using CLSM after 20 min.
In vivo distribution of PLGA-lysoGM1/DOX micelles in mice
PLGA-lysoGM1/DOX micelles were injected into mice to 
quantitatively analyse the BBB penetration as we previously 
described.50 Male Kunming (KM) mice, weighing 20-23 g, were 
provided by the Laboratory Animal Center, Chongqing Medical 
University. The animal experimentation was approved by the 
Chongqing University Animal Experimentation Committee and 
was conducted in accordance with the ethical guidelines, in 
compliance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals. The mice were starved 
for 12 h before receiving a single dose (18 µg/each) of the DiR 
solution and PLGA/DiR NPs, PLGA-lysoGM1/DiR micelles 
intravenously. Then the fluorescent distribution of whole body 
was observed by an IVIS imaging system (IVIS Spectrum, 
Xenogen, Perkin-Elmer, China) after anesthesia. At 30 min, 90 
min, and 8 h after administration of PLGA-lysoGM1/DiR 
micelles, the mice were sacrificed after perfusion, and the 
main organs (brain, heart, liver, spleen, lung, kidney) were 
carefully excised to compare the different accumulation levels. 
1.5 mL DOX solution (0.45 mg/mL), PLGA/DOX NPs or 
PLGA-lysoGM1/DOX micelles were injected through the tail 
vein of male wistar rats (250 ± 10 g, Weitong Lihua Animal 
Technology Co. Ltd., Beijing, China) at different scheduled 
times. The content of DOX in CSF was then measured by HPLC 
(1260 Agilent, Santa Clare, CA, USA), C18 - MS (COSMOSIL5, 
250 mm × 4. 6 mm, 5 μm) column, mobile phase: acetonitrile: 
SDS (60: 40), flow rate (0.8 mL/min), detection wavelength 
(254 nm), injection volume (20 μL).
In vivo anti-glioma effect
C6 glioma-bearing male wistar rats were established following 
the procedures described in our previous literature.50 In detail, 
the male wistar rats were anesthetized by an intraperitoneal 
injection with 4% chloral hydrate. The C6 cells (5 × 105 C6 
glioma cells suspended in 20 µL 1640 medium) were implanted 
into the right striatum (1.8 mm lateral, 1.0 mm longitudinal, 
and 4.5 mm depth) of the rats using a brain stereotactic 
fixation device. 20 d after implantation, rats were randomly 
divided into five groups (10 rats per group). At day 8, 11, 13, 
each group of rats were intravenously injected with normal 
saline, free DOX, free GM1, PLGA/DOX NPs and PLGA-
lysoGM1/DOX micelles and the administration dose of DOX 
was 2.25 mg/kg. For all groups, the overall Kaplan-Meier 
survival curves and neurological score were monitored. In 
addition, three rats from each group were sacrificed on 20 d, 
the tumour size of rats was measured by MRI (MAGNETOM 
Avanto 1.5T, Siemens, Berlin, Germany), and brains were 
sampled for H&E staining and immunohistochemical staining.
Statistical analysis
All experimental data consisted of mean and standard 
deviation. Data were subjected to t-test and significant 
differences between the two groups were calculated using 
SPSS 13.0 software. P < 0.05, 0.01, and 0.001 were considered 
a statistically significant difference and remarked with *, **, 
and ***, respectively.
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Graphical abstract. (a) Diagram depicting the preparation of the PLGA-lysoGM1/DOX micelles 
drug delivery system. (b) Schematic illustration of PLGA-lysoGM1/DOX micelles acting against 
glioma. (c) Magnified schematic showing PLGA-lysoGM1/DOX micelles crossing the BBB 
through macropinocytosis and autophagy/lysosomal pathways.
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